-
05:01:43 PM
Sign in with email
Forgot your password?
Register with email
Account Verification

AZN Stock News

10/03/22 7:15 AM
Nasdaq : AZN, LOGC
acquisition
Alexion, AstraZeneca Rare Disease to Acquire LogicBio(R) Therapeutics to Accelerate Growth in Genomic Medicine
Alexion, AstraZeneca Rare Disease, today announced that it has entered a definitive agreement to acquire Lexington, Mass.- based LogicBio (R) Therapeutics, Inc., a pioneering genomic medicine company. The scientific collaboration between Alexion and AstraZeneca has been a substantial area of focus since last year' s acquisition and the addition of LogicBio...
RHEA-AI
very positive
09/16/22 7:10 AM
Nasdaq : AZN
clinical trial
Danicopan (ALXN2040) Add-On to ULTOMIRIS(R) (ravulizumab-cwvz) or SOLIRIS(R) (eculizumab) Met Primary Endpoint in ALPHA Phase III Trial for Patients with Paroxysmal Nocturnal Hemoglobinuria Who Experience Clinically Significant Extravascular Hemolysis
A prespecified interim analysis of the ALPHA Phase III trial evaluating danicopan, an investigational, oral factor D inhibitor, as an add-on to C5 inhibitor therapy ULTOMIRIS (R) or SOLIRIS (R) showed positive high-level results in patients with paroxysmal nocturnal hemoglobinuria who experience clinically significant extravascular hemolysis.
RHEA-AI
neutral
09/15/22 12:00 PM
Nasdaq : AZN
partnershipcovid-19
AstraZeneca Partners with Jeff Bridges, Kumail Nanjiani, and Emily V. Gordon to Educate the Immunocompromised Community about Added Protection Against COVID-19
Today, AstraZeneca launched Up The Antibodies, an important new campaign that embraces the reality for millions of immunocompromised Americans 1,2: COVID-19 isn' t over. Up The Antibodies, a new educational campaign from AstraZeneca with Jeff Bridges and other iconic voices to help educate the immunocompromised community about added protection against...
RHEA-AI
neutral
09/12/22 11:05 AM
Nasdaq : AZN
IMFINZI(R) (durvalumab) plus chemotherapy further improved overall survival benefit in advanced biliary tract cancer in the TOPAZ-1 Phase III trial, reducing the risk of death by 24% in additional follow-up
Updated results from the TOPAZ-1 Phase III trial showed AstraZeneca' s IMFINZI (R), in combination with standard-of-care chemotherapy demonstrated a clinically meaningful and durable overall survival benefit as a treatment for patients with advanced biliary tract cancer. These results from TOPAZ-1, the first Phase III trial to show improved OS with an...
RHEA-AI
neutral
09/11/22 9:35 AM
Nasdaq : AZN
ENHERTU(R) (fam-trastuzumab deruxtecan-nxki) Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2-mutant Metastatic Non-small Cell Lung Cancer
ENHERTU is a specifically engineered HER2-directed antibody drug conjugate being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo. Koichi Goto, MD, Medical Oncologist and Investigator at National Cancer Center Hospital East, Kashiwa, Japan, said:" DESTINY-Lung02 reinforces HER2 as an actionable mutation in patients with...
RHEA-AI
neutral
09/11/22 8:05 AM
Nasdaq : AZN
IMFINZI(R) (durvalumab) and tremelimumab with chemotherapy demonstrated sustained survival benefit in metastatic non-small cell lung cancer, nearly doubling the number of patients alive after three years vs. chemotherapy
These late-breaking results were presented today at the European Society of Medical Oncology Congress 2022. Melissa Johnson, MD, Director of Lung Cancer Research, Sarah Cannon Research Institute at Tennessee Oncology in Nashville, Tennessee, and a lead investigator in the POSEIDON Phase III trial, said: "Metastatic non-small cell lung cancer is a devastating...
RHEA-AI
neutral
09/11/22 8:00 AM
Nasdaq : AZN
TAGRISSO(R) (osimertinib) demonstrated 5.5-year median disease-free survival in the adjuvant treatment of patients with EGFR-mutated lung cancer
These late-breaking results will be presented today at the European Society for Medical Oncology Congress 2022 in Paris. Masahiro Tsuboi, MD, PhD, Chief and Director, Department of Thoracic Surgery& Oncology, National Cancer Center Hospital East, Japan, and principal investigator in the ADAURA trial, said:" The updated ADAURA results show us that adjuvant...
RHEA-AI
neutral
09/11/22 4:15 AM
Nasdaq : AZN
ENHERTU(R) Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2 Mutant Metastatic Non-Small Cell Lung Cancer
Detailed positive results from an interim analysis of the DESTINY-Lung02 phase 2 trial showed ENHERTU (R) demonstrated clinically meaningful tumor responses in previously treated patients with HER2 mutant unresectable and/or metastatic non-squamous non-small cell lung cancer. Results will be presented today as a late...
RHEA-AI
neutral
09/09/22 8:00 AM
Nasdaq : AZN
LYNPARZA(R) (olaparib) in Combination with Bevacizumab, and as a Monotherapy, Demonstrates Clinically Meaningful Survival Benefit in 1st-Line Advanced Ovarian Cancer Across Two Phase III Trials
Positive long-term follow-up results from the PAOLA-1 and SOLO-1 Phase III trials of LYNPARZA (R), jointly developed and commercialized by AstraZeneca and Merck& Co., Inc., known as MSD outside the US and Canada, with or without bevacizumab demonstrated clinically meaningful improvements in overall survival. The results for PAOLA-1 and SOLO-1 were...
RHEA-AI
neutral
09/05/22 7:00 AM
Nasdaq : AZN
IMFINZI(R) (durvalumab) Plus Chemotherapy Approved in the US as the First Immunotherapy Regimen for Patients with Advanced Biliary Tract Cancer
AstraZeneca' s IMFINZI (R) has been approved in the US for the treatment of adult patients with locally advanced or metastatic biliary tract cancer in combination with chemotherapy. The approval by the Food and Drug Administration was based on the results from the TOPAZ-1 Phase III trial. Aiwu Ruth He, MD, PhD, Associate Professor of Medicine, Leader of the GI...
RHEA-AI
neutral